Tevogen Bio Holdings Inc. 8-K

What Happened Tevogen Bio Holdings, Inc. (TVGN) filed an 8-K (Item 3.01) reporting that Nasdaq’s Listing Qualifications Staff notified the company in mid‑April 2026 that it does not meet two market‑value listing requirements. On April 16, 2026 Nasdaq said the company’s market value of listed securities fell below the $50 million minimum (Nasdaq Listing Rule 5450(b)(2)(A)). On April 17, 2026 Nasdaq said the market value of publicly held shares fell below the $15 million minimum (Nasdaq Listing Rule 5450(b)(2&3)(C)). These notices do not immediately affect trading or listing.

Key Details

• Nasdaq provided a 180‑day cure period for each deficiency: MVLS compliance deadline is October 13, 2026; MVPHS compliance deadline is October 14, 2026.
• To regain compliance, the company’s market value must close at or above the applicable threshold for a minimum of 10 consecutive business days (generally up to 20 days) before the deadline.
• The company said it will monitor market values and may consider options (including a possible transfer to The Nasdaq Capital Market), but gave no assurance it will take or succeed with any specific action.

Why It Matters This filing alerts investors that Tevogen currently fails Nasdaq’s market‑value tests and faces possible delisting if it cannot restore the required market values by mid‑October 2026. While trading continues for now, failure to regain compliance could lead to heightened volatility, reduced liquidity, and potential listing transfer or delisting—factors that can affect share price and investor access. The company’s stated next steps are monitoring and evaluating options, but outcomes are not guaranteed.